Cargando…

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

BACKGROUND: Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor therapy. Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulating factor ‐secreting cellular immunotherapy that induces...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yarchoan, Mark, Huang, Chiung‐Yu, Zhu, Qingfeng, Ferguson, Anna K., Durham, Jennifer N., Anders, Robert A., Thompson, Elizabeth D., Rozich, Noah S., Thomas, Dwayne L., Nauroth, Julie M., Rodriguez, Christina, Osipov, Arsen, De Jesus‐Acosta, Ana, Le, Dung T., Murphy, Adrian G., Laheru, Daniel, Donehower, Ross C., Jaffee, Elizabeth M., Zheng, Lei, Azad, Nilofer S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013064/ https://www.ncbi.nlm.nih.gov/pubmed/31876399 http://dx.doi.org/10.1002/cam4.2763

Ejemplares similares

Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)
por: Le, Dung T, et al.
Publicado: (2015)

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
por: Yarchoan, Mark, et al.
Publicado: (2017)

Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer
por: Nair, Nitya, et al.
Publicado: (2015)

S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014)

A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
por: Bever, Katherine M., et al.
Publicado: (2021)

A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study)
por: Wang-Gillam, Andrea, et al.
Publicado: (2014)

MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity
por: Yarchoan, Mark, et al.
Publicado: (2019)

Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer
por: Christenson, Eric S., et al.
Publicado: (2022)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
por: Lipson, Evan J, et al.
Publicado: (2015)

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
por: Santegoets, Saskia JAM, et al.
Publicado: (2014)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
por: Diehl, Adam, et al.
Publicado: (2017)

Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy
por: Ho, Won Jin, et al.
Publicado: (2020)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy
por: Qin, L, et al.
Publicado: (2013)

Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
por: Li, Keyu, et al.
Publicado: (2022)

Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge
por: Griffith, Paige, et al.
Publicado: (2022)

Residents’ proficiency in diagnostics with all ophthalmic equipment – Need of the hour
por: Sinha, Sony, et al.
Publicado: (2021)

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
por: Anders, Carey K, et al.
Publicado: (2022)

Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
por: Mery, Benoîte, et al.
Publicado: (2023)

A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
por: Baretti, Marina, et al.
Publicado: (2023)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
por: Routh, Eric D, et al.
Publicado: (2023)

Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses
por: Jayaraman, Sahana, et al.
Publicado: (2023)

HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
por: Bacigalupo, Andrea, et al.
Publicado: (2016)

Comparison of proteomic and genomic analyses of vaccine cell lines shows men receiving prostate gvax immunotherapy develop increased humoral responses to common cell line proteins relative to mutated proteins
por: Hulett, Tyler, et al.
Publicado: (2014)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Influences of persistent overweight on perceptual-motor proficiency of primary school children: the North-West CHILD longitudinal study: Persistent overweight and perceptual-motor proficiency in children
por: de Waal, Elna, et al.
Publicado: (2021)

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2021)

A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma
por: Heumann, Thatcher, et al.
Publicado: (2023)

Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer
por: Baretti, Marina, et al.
Publicado: (2022)

Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells
por: Schwarz, V A, et al.
Publicado: (2002)

GenomeTrakr proficiency testing for foodborne pathogen surveillance: an exercise from 2015
por: Timme, Ruth E., et al.
Publicado: (2018)

Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development
por: Zaidi, Neeha, et al.
Publicado: (2020)

Formation and Evaluation of Complete Blood Count Proficiency Testing Program
por: Vu, Huy Quang, et al.
Publicado: (2022)

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2022)

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
por: Chan, T A, et al.
Publicado: (2019)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hmhe84r17qr9e2v69p0j8ts9a6